Navigation Links
FDA awards $2.25M grant to study immunosuppresive drug in high-risk patients

CINCINNATITransplant researchers at the University of Cincinnati (UC) have received a grant from the U.S. Food and Drug Administration to study the safety and efficacy of a generic immunosuppressive drug in high-risk transplant patients.

Rita Alloway, PharmD, UC research professor of medicine and director of transplant clinical research within the UC Department of Internal Medicine, received a $2.25 million FDA grant to run two clinical trials studying the effects of immunosuppressant tacrolimus (Prograf and generics) in high-risk transplant patients.

Tacrolimus is a "cornerstone drug" in post-transplant immunosuppression, used after transplant to reduce the activity of the patient's immune system and lower the risk of rejection. Generic versions were introduced in 2009. Currently Alloway estimates more than 70 percent of transplant patients are dispensed generic tacrolimus.

"The largest concern for clinicians is the switchability between various generics," says Alloway. "When patients receive their prescription, they could be getting medication from different manufacturers each month. Most immunosuppressant drugs require individualized dosing and careful management to ensure the proper blood concentrations are maintainedtoo high exposure to these drugs increases the risk of toxicity, over-immunosuppression and cancer in patents. Too low exposure may lead to rejection of the organ by the patient's immune system."

The three-year grant will support retrospective and prospective studies in high-risk transplant recipients who have converted from branded tacrolimus to a generic version.

In the retrospective study, transplant recipients will be assessed one year prior and one year post conversion to the generic, with researchers assessing their tacrolimus dose changes, incidence of rejection, hospital admission, changes in renal function and changes in transplanted organ function.

The prospective study will compare the bioavailability and steady-state pharmacokinetics of six tacrolimus formulations in a six-way cross-over study. This study will compare patients who express the CYP3A5 enzyme and those who do not, as CYP3A5 expressors have been shown to require larger doses of tacrolimus to attain therapeutic blood concentrations.

Preliminary data from Alloway's tacrolimus research has suggested a link between CYP3A5 expression and peak tacrolimus levels after dosing in generic tacrolimus formulations.

"This study will analyze an enriched patient population based upon genetic factors which predispose the patient to be high risk and most likely to experience problems with generic switching if problems exist," states Alloway.

In 2012, Alloway received a $2.7 million grant from the FDA to study whether the two most disparate generic versions of tacrolimus are bioequivalent to the branded, or innovator, version of the drug in stable transplant patients.

"The results of these studies should address public concerns regarding the use of generic tacrolimus formulations in transplant recipients and provide the transplant clinician and recipients with objective data to address their concerns," she says.


Contact: Katy Cosse
University of Cincinnati Academic Health Center

Related medicine news :

1. T.E.N. Announces Winners of the ISE® North America Awards
2. The Global Awards World’s Best Healthcare Advertising Hosts Celebrations in New York City & Sydney, Australia
3. The Optical Society Presents Awards to Winners of Its Inaugural ‘Enabled by Optics’
4. Wells Fargo Supports Hospice Care as Diamond Sponsor of Pathways Hospice Awards Breakfast
5. Reviews "Face Fitness Formula" and Awards the Latest Guide Released by Face Fitness Center
6. Force Marketing Honored in Inc. Magazine Hire Power Awards for 2013
7. The Home Depot Foundation Awards Swords to Plowshares $24,000 to Renovate Housing for Veteran Families
8. Barton Publishing Honored as Silver Winner in 2013 Golden Bridge Awards “Best Customer Satisfaction Program of the Year”
9. National Robotics Initiative Awards provide $7 million for Carnegie Mellon research projects
10. American Eurocopter Awards Honor Leaders in Air Medical Safety
11. IPM receives 2 awards from USAID to advance HIV prevention technologies for women
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... On November 10, 2015, Bohrer Brady, LLC filed ... on behalf of a home health care worker who provided companionship services for the ... care workers employed by Humana, Inc., Humana at Home, Inc., and SeniorBridge Family Companies ...
(Date:11/25/2015)... ... November 25, 2015 , ... Lakeview Health, ... country to celebrate their sobriety and show through pictures what a positive difference ... photos this Thanksgiving with the hashtag #FacesOfGratitude on their Facebook, Twitter, and Instagram ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... for physicians and athletic programs, launches new Wimbledon Athletics Facebook page ... testing young athletes for unsuspected cardiac abnormalities. About 2,000 people under the age ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of Botox® for ... aware of the benefits of Botox® in the treatment of moderate facial wrinkling, few ... and pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, and Bruxism ...
(Date:11/25/2015)... ... November 25, 2015 , ... Brillianteen, McGaw YMCA’s student-produced ... in its 65th Anniversary Brillianteen Revue, scheduled for March 4-6, 2016. Auditions for ... years, Brillianteen has been a treasured tradition for numerous families in the Evanston ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 ... of the "2016 Future Horizons and ... Abuse Testing Market: Supplier Shares, Country Segment ... to their offering. --> ... "2016 Future Horizons and Growth Strategies ...
(Date:11/26/2015)... 2015 ... the  "2016 Future Horizons and Growth ... Monitoring (TDM) Market: Supplier Shares, Country ...  report to their offering.  --> ... addition of the  "2016 Future Horizons ...
(Date:11/26/2015)... , November 26, 2015 ... the addition of the  "2016 Future ... European Cell Surface Marker Testing Market: ...  report to their offering.  --> ... addition of the  "2016 Future Horizons ...
Breaking Medicine Technology: